438 related articles for article (PubMed ID: 17875774)
1. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
3. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
4. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
5. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
9. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Oncol Rep; 2005 Feb; 13(2):253-7. PubMed ID: 15643507
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.
Holt SV; Brookes KE; Dive C; Makin GW
Oncol Rep; 2011 Apr; 25(4):1177-81. PubMed ID: 21286665
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
15. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.
Lollini PL; Landuzzi L; Frabetti F; Rossi I; Nicoletti G; Scotlandi K; Serra M; Baldini N; De Giovanni C; Nanni P
Clin Cancer Res; 1998 Aug; 4(8):1843-9. PubMed ID: 9717810
[TBL] [Abstract][Full Text] [Related]
16. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity.
Zhou Z; Lafleur EA; Koshkina NV; Worth LL; Lester MS; Kleinerman ES
Mol Cancer Res; 2005 Dec; 3(12):685-91. PubMed ID: 16380506
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235 as a new therapeutic option for sarcomas.
Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
[TBL] [Abstract][Full Text] [Related]
19. The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies.
Velez-Yanguas MC; Warrier RP
Orthop Clin North Am; 1996 Jul; 27(3):545-9. PubMed ID: 8649735
[TBL] [Abstract][Full Text] [Related]
20. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]